
The Federal Trade Commission has said it will remove Mark Zuckerberg, the chief executive of Meta, from a lawsuit to block the company’s acquisition of Within Unlimited, an artificial intelligence start-up.
The agency said in a court filing on Tuesday that it agreed to drop Mr. Zuckerberg as a defendant after Meta, formerly known as Facebook, promised he would not try to personally purchase Within Unlimited. Meta had asked the agency to remove Mr. Zuckerberg as a defendant.
In June, the F.T.C. filed its complaint with U.S. District Court for the Northern District of California to prevent Meta and Mr. Zuckerberg from acquiring Within, which makes the popular virtual-reality fitness app Supernatural. The F.T.C. included Mr. Zuckerberg as a defendant in the suit and accused him and Meta of planning to buy Within to dominate the nascent virtual-reality market and violate antitrust laws.
Related Content: FTC’s case against Meta’s acquisition of Within seeks to shape the emerging VR market
The lawsuit — which is part of a new strategy by Lina Khan, the F.T.C. chair, to be more forward-looking in antitrust enforcement — is considered a long shot by many legal experts because it involves an acquisition in a nascent market with many start-ups. In the past, most antitrust court cases involved more mature markets and focused on how a merger can lead to higher prices for consumers.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas